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Abstract
Introduction: Tamoxifen and raloxifene are chemopreventive drugs that can reduce women’s relative risk of
primary breast cancer by 50%; however, most women eligible for these drugs have chosen not to take them. The
reasons for low uptake may be related to women’s knowledge or attitudes towards the drugs. We aimed to
examine the impact of an online breast cancer chemoprevention decision aid (DA) on informed intentions and
decisions of women at high risk of breast cancer.
Methods: We conducted a randomized clinical trial, assessing the effect of a DA about breast cancer
chemoprevention on informed choices about chemoprevention. Women (n = 585), 46- to 74-years old old,
completed online baseline, post-test, and three-month follow-up questionnaires. Participants were randomly
assigned to either an intervention group, a standard control group that answered questions about
chemoprevention at baseline, or a three-month control group that did not answer questions about
chemoprevention at baseline. The main outcome measures were whether women’s intentions and decisions
regarding chemoprevention drugs were informed, and whether women who viewed the DA were more likely to
make informed decisions than women who did not view the DA, using a dichotomous composite variable
‘informed choice’ (yes/no) to classify informed decisions as those reflecting sufficient knowledge and concordance
between a woman’s decision and relevant attitudes.
Results: Analyses showed that more intervention than standard control participants (52.7% versus 5.9%) made
informed decisions at post-test, P <0.001. At the three-month follow-up, differences in rates of informed choice
between intervention (16.9%) and both control groups (11.8% and 8.0%) were statistically non-significant, P = 0.067.
Conclusions: The DA increased informed decision making about breast cancer chemoprevention, although the
impact on knowledge diminished over time. This study was not designed to determine how much knowledge
decision makers must retain over time. Examining informed decisions increases understanding of the impact of
DAs. A standard for defining and measuring sufficient knowledge for informed decisions is needed.
Trial registration: ClinicalTrials.gov: NCT00967824
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Introduction
Tamoxifen and raloxifene are chemopreventive drugs that
can reduce women’s relative risk of primary breast cancer
by 50% [1,2]. Tamoxifen has been available for chemopre-
vention for more than 10 years, and raloxifene was
approved in 2006 for post-menopausal women. When the
efficacy of these drugs for breast cancer prevention was
established, it was initially believed they would provide a
desirable option for reducing the risk of breast cancer and
that these drugs might bring about a ‘new era of preven-
tive therapeutics that could revolutionize women’s
health’[3]. However, most women eligible for these drugs
have chosen not to take them [4-8].
A number of factors relating to women’s knowledge
and attitudes towards these drugs appear to contribute to
the low uptake. First, women are not necessarily aware of
their availability - previous research found women’s
awareness of tamoxifen varied widely between ethnic
groups, with white women most frequently reporting
awareness of the drugs [9]. Second, women may not
believe the drugs can truly reduce their risk of breast
cancer [8,10-12]. Third, while raloxifene was originally
designed to treat osteoporosis, tamoxifen was designed to
prevent recurrence of breast cancer and, therefore, may
have negative connotations [13]. Fourth, fear of potential
side effects may inhibit positive attitudes toward taking
chemoprevention drugs [5], including a perception that
the potential risks (that is, increased risks of endometrial
cancer, pulmonary embolism, stroke, deep vein thrombo-
sis, cataracts, hormonal symptoms and sexual problems)
outweigh the potential benefits of the drugs (that is,
reduced risks of breast cancer and osteoporosis)
[4,5,7,10,12,14]. Finally, many people, particularly when
healthy, are opposed to taking preventive drugs on a
regular basis [5,12].
Deciding whether to start chemoprevention is a prefer-
ence sensitive decision, meaning there is not one superior
choice [15]. To make the best decision for themselves,
individuals need unbiased information [16] to consider the
risks and benefits of each choice as well as their values
and goals.
At present, there is no standard measure of informed
choice for cancer prevention or detection behaviors. In
this manuscript we adapt the concept of the Multidimen-
sional Measure of Informed Choice (MMIC) as developed
by Marteau and colleagues, which relates to the dimen-
sions of knowledge, people’s attitudes regarding the choice
options and the extent to which choice reflects attitudes
[17,18]. This concept was, in turn, adapted from O’Connor
and O’Brien-Pallas’ [19] definition of an effective decision:
‘one that is based on relevant knowledge, consistent with
the decision-maker’s values and behaviorally implemen-
ted.’ Marteau’s definition states that an informed choice to
engage in chemoprevention behavior occurs when a
woman: 1) has sufficient relevant knowledge about
chemoprevention behavior; 2) has positive attitudes
toward engaging in chemoprevention; and 3) engages in
chemopreventive behavior. It also occurs when a woman:
1) has sufficient relevant knowledge about chemopreven-
tion behavior; 2) negative attitudes toward engaging in
chemoprevention; and 3) does not engage in chemopre-
ventive behavior [17]. Although decisions resulting from
other combinations of these factors are traditionally
considered uninformed, either because of insufficient deci-
sion-relevant knowledge or because of incongruence
between attitudes and behavior, we define a third type of
informed decision; specifically, women with: 1) sufficient
relevant knowledge; 2) ambivalent attitudes toward
chemoprevention; and 3) who are undecided or uncertain
about whether to engage in chemoprevention. Chemopre-
vention decisions are not time-sensitive in the same way
that treatment decisions are and waiting to make a choice
as a result of ambivalence is quite rational, given there is
little cost to delay. We characterize the choice to delay
decision-making about chemoprevention due to ambiva-
lent or neutral attitudes as informed since women may
still be in the process of making a decision; their lack of a
decision accurately reflects their ambivalent attitudes.
To date, we are unaware of other studies that have
assessed the impact of a decision aid (DA) on women’s
informed decisions about breast cancer chemoprevention.
Aiming to address this gap, a randomized controlled trial
was conducted in 2007/2008 to test a tailored, online
breast cancer chemoprevention DA. The ‘Guide to Decide’
DA provided tailored information (see section 2.3 for
details) to women at increased risk of breast cancer about
the risks and benefits of tamoxifen and raloxifene [20].
Women’s knowledge, attitudes and behavioral intentions
to take chemoprevention drugs were assessed immediately
after viewing the DA and their uptake behavior three
months later. The primary outcomes were whether
women’s decisions regarding chemoprevention drugs were
informed and whether women who viewed the DA were
more likely to make informed decisions than women who
did not view the DA.
Methods
Participant recruitment
After obtaining Institutional Review Board approval
from the University of Michigan and two health care
delivery systems (Henry Ford Health System in Detroit,
MI and Group Health Cooperative in Seattle, WA) and
registering the trial (http://ClinicalTrials.gov; number
NCT00967824), electronic medical records were used to
create a list of eligible women - specifically women at
high risk of developing invasive breast cancer, defined
by a five-year risk of ≥1.66% on the Breast Cancer Risk
Assessment Tool (BCRAT, based on the Gail model)
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[19-21] and without contraindications to tamoxifen or
raloxifene. We sent these women invitation letters with
a description of the study, the study website, and a user-
name and password. There was no racial bias in the
selection of participants. Interested women logged in
and were screened for final eligibility based on self-
report. Eligible women were between 40 and 74 years
old, (as chemoprevention is only approved for those
ages) and were post-menopausal (raloxifene is only
approved for post-menopausal women [21]). Women
were excluded if they reported a prior history of breast
cancer or tamoxifen or raloxifene use, contraindications
to tamoxifen or raloxifene, participation in the Study of
Tamoxifen and Raloxifene (STAR) trial [21], terminal
illness, or were currently pregnant or nursing.
Randomization to intervention and control groups
A total of 1,039 women gave their informed consent to
participate in the study. Due to a computer error, only
1,012 of them were correctly randomized (see Figure 1,
the flow diagram). This report is limited to the 585 of the
1,039 (57.8%) women who completed the three-month
follow-up survey.
After completing eligibility screening and the baseline
questionnaire, participants were randomly assigned to one
of three groups: intervention, standard control, or three-
month control as previously described by Fagerlin and
colleagues [8] (Figure 1). Intervention group participants
received the Guide to Decide DA (described below) imme-
diately after randomization and then completed a post-test
questionnaire. Standard control group participants did not
receive the DA until they completed the three-month
follow-up, but completed the same questionnaires as the
intervention group. Since participants in the standard
control group might seek information (that is, “Google’
tamoxifen and raloxifene) after having answered questions
about chemoprevention without receiving any informa-
tion, we included the three-month control group. Partici-
pants in this group answered chemoprevention questions
at the three-month follow-up, but neither received the DA
nor answered any questions about chemoprevention at the
time of enrollment, which ensured the inclusion of a con-
trol group without previous exposure to chemoprevention
information. Analyses examining the immediate effect of
the DA compare participants from the intervention group
to the standard control group, and analyses examining the
longer-term effect of the DA compare participants from
the intervention group to both control groups.
The ‘Guide to Decide’ decision aid intervention
The Guide to Decide DA provided general information
about breast cancer, tamoxifen and raloxifene [1]. Women
received tailored (personalized) information about their
individual five-year risk of breast cancer according to their
scores on the BCRAT [20]. Side effect rates were tailored
to each woman’s age and race. This information included
estimates of the risks of endometrial cancer, blood clotting
problems, cataracts, hormone symptoms, sexual problems,
breast cancer and bone fractures. The DA was written at
approximately an eighth grade reading level. Further details
about the development and tailoring of the Guide to
Decide DA intervention have been published previously [8].
Measures
Knowledge of risks and benefits of chemoprevention
Women’s gist knowledge (’the ability to identify the essen-
tial point of the information presented’) of the risks and
benefits of each drug was measured through questions
such as, ‘Please tell us whether you think taking tamoxifen
(or raloxifene) will make you less likely, more likely, or
have no difference in the likelihood that you would experi-
ence each of the health conditions listed below.’ Partici-
pants were then given a list of two risks (increased risk of
hormonal symptoms and cataracts) and two benefits
(decreased risk of broken bones and breast cancer) of
tamoxifen (or raloxifene) and were asked to answer the
likelihood question for each risk and benefit. Each
question was asked for both tamoxifen and raloxifene. The
intervention and standard control groups answered these
knowledge questions at post-test and three-month follow-
up, while the three-month control group only answered
them at three-month follow-up.
Based on other researchers’ work, we assessed distri-
butions of accurate knowledge in the data and operatio-
nalized a ‘sufficient level of decision-relevant knowledge’
as answering at least 50% of the items (4 of 8) correctly
Figure 1 Flow diagram of study populations and assessment.
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and ‘insufficient decision-relevant knowledge’ as three or
fewer correctly answered items [22].
Attitudes toward chemopreventive drugs
Women were asked, ‘How good of a choice is taking
tamoxifen (or raloxifene) as a way to reduce your chance
of getting breast cancer?’ (1 = ‘For me it is not a good
choice at all,’ to 5 = ‘For me it is an extremely good
choice’). Response options were worded to assess atti-
tudes toward own behavior rather than attitudes toward
tamoxifen in general (for example, a woman may feel
chemoprevention is a good option for others but feel it is
not a good choice for her personally). Responses 1 and 2
were classified as ‘negative attitudes’ and responses 4 and
5 as ‘positive attitudes’. The midpoint response option 3
was classified as ‘neutral attitudes’ [22].
Behavioral intentions
Behavioral intentions to take chemoprevention drugs in
the post-test survey were measured using ‘Given what you
know right now, how likely doyou think you are to take a
breast cancer prevention drug in the next year?’ (1 = ‘not
at all likely,’ to 5 = ‘extremely likely’). Responses 1 and 2
were classified as not likely to engage in chemoprevention
behavior, response 3 was classified as neutral about
engagement, and responses 4 and 5 were classified as likely
to engage in chemoprevention behavior.
Actual behavior
Chemoprevention uptake behavior was measured in all
three groups at follow-up by asking participants, ‘Have
you made a decision about whether or not to take a
breast cancer prevention drug as a way to prevent breast
cancer?’ (1 = ‘no decision yet’; 2 = ‘decided to take
Tamoxifen’; 3 = ‘decided to take Raloxifene’; 4 = ‘decided
to take no drug’).
Informed or uninformed decision
A dichotomous variable was created, ‘informed decision,’
(yes/no) representing participants with sufficient knowl-
edge about chemoprevention behavior (assessed at post-
test and follow-up), whose attitudes were concordant with
their intentions (at post-test) or decisions (at follow-up) to
engage in chemoprevention behavior.
According to Fuzzy Trace Theory [23], it is possible that
participants made an initial decision at post-test based on
their knowledge and attitudes at that time, and then forgot
details by follow-up but remembered their general deci-
sion. These participants would, therefore, make a decision
at follow-up based on their initial (post-test) knowledge
and feelings. Three different ‘informed decision’ scores
were calculated to account for the various ways partici-
pants may have arrived at an informed decision. Post-test
knowledge, attitudes and intentions were used for the
‘post-test informed decision’ score. Follow-up knowledge,
attitudes and behavior were used for the ‘follow-up
informed decision’ score. Finally, post-test knowledge and
follow-up attitudes and behavior were used for the ‘latent
knowledge informed decision’ score.
Covariates
At baseline, age, race and ethnicity, and educational
background were assessed. Educational background was
condensed into three levels of education (high school or
less, some college or trade school, and bachelor’s degree
or higher).
Participants completed standardized individual difference
measures of subjective numeracy [24,25] and health, using
the single item, ‘How would you rate your health?’ (1 =
poor, 2 = fair, 3 = good, 4 = very good and 5 = excellent).
Analyses
We calculated means, standard deviations and frequen-
cies to describe the participants and experimental groups.
Inferential statistics include t-tests, analysis of variance,
and Pearson chi-square analysis (2-tailed significance).
Results
Participants
A total of 585 women completed the study through the
three-month follow-up (see Figure 1 for details on
participant flow through the intervention). Table 1
describes participants’ baseline characteristics. On aver-
age, participants were 61.6 (SD = 5.2) years old, mostly
white (98%) and well educated (71% had at least a
bachelor’s degree). BCRAT scores ranged from 1.7% to
19.1% (M = 2.67, SD = 1.37).
Post-test knowledge, attitudes and behavioral intentions
More intervention participants (62%) than standard con-
trol participants (7%) met the criteria for ‘sufficient
knowledge,’ Χ2(1) = 97.53, P <.001 (answering at least 4
out of 8 questions correctly) (Table 2).
When asked ‘How good of a choice is taking a breast
cancer prevention drug as a way to reduce your chance
of getting breast cancer?’, 75% of the intervention group
and 62% of the standard control group indicated negative
attitudes toward taking chemoprevention themselves.
Intervention participants reported 19% neutral attitudes
and 6% positive attitudes, and standard control partici-
pants reported 35% neutral attitudes and 3% positive
attitudes (Table 2). Distribution of attitudes varied signifi-
cantly between the intervention and standard control
groups, (Χ2(2) = 12.64, P = .002).
Intervention participants (4%) were more likely to
intend to start chemoprevention than standard control
participants (3%), Χ2(2) = 6.38, P = 0.041 (Table 2).
At post-test, participants in the intervention group were
not more likely to demonstrate alignment of attitudes and
intentions than those in the standard control group, X2(1)
= 0.077, P = 0.78 (data not shown).
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Post-test informed choice
In the intervention group, 53% of the decisions about
intentions to take chemoprevention were informed, in that
participants had both sufficient knowledge and alignment
of attitudes and intentions (Table 3). In the majority of
cases (89%), these were decisions of women who had suffi-
cient knowledge, negative attitudes toward uptake and no
intentions to take tamoxifen or raloxifene. Uninformed
decisions were mainly due to low levels of decision-
relevant knowledge. Compared to intervention partici-
pants, fewer standard control participants (6%) made an
informed decision (X2(1) = 71.97, P <0.001, Table 3). Most
(93.1%) standard control participants did not have suffi-
cient knowledge to make an informed decision (Table 2).








Age, mean (SD) 61.50 (5.05) 62.10 (5.25) 61.51 (5.63) F(2, 582) = 0.55, P = .58
Age, over 60 249 (65.0%) 67 (65.7%) 65 (65.0%) X2(2) = 0.02, P = .99
Education
High school education or less 19 (5.0%) 3 (2.9%) 7 (7.0%) X2(4) = 3.69, P = .45
Some college or trade school 84 (22.2%) 29 (28.4%) 26 (26.0%)
Four-year college degree or more 276 (72.8%) 70 (68.6%) 67 (67.0%)
Race
Hispanic 1 (0.3%) 0 (0%) 0 (0%) X2(2) = 0.53, P = .77
White 374 (97.7%) 99 (97.1%) 99 (99.0%) X2(2) = 0.96, P = .62
Black 2 (0.5%) 0 (0%) 0 (0%) X2(2) = 1.06, P = .59
BCRAT score (SD) 2.67 (1.19) 2.55 (0.92) 2.82 (2.16) F(2, 582) = 1.06, P = .35
Subjective Numeracy Scale 4.48 (0.94) 4.53 (0.95) 4.29 (0.99) F(2, 582) = 1.87, P = .16













146 (38.1%) 95 (93.1%) Χ2(1 9 7.53, P <.001
Sufficient 237 (61.9%) 7 (6.9%)
Attitudes Negative 284 (74.9%) 61 (61.6%) Χ2(2) = 12.64, P =
.002
Neutral 72 (19.0%) 35 (35.4%)
Positive 23 (6.1%) 3 (3.0%)
Intention for
uptake
Not likely 323 (85.2%) 78 (77.2%) Χ2(2) = 6.38, P =
.041
Neutral 40 (10.6%) 20 (19.8%)
Likely 16 (4.2%) 3 (3.0%)
Three-month follow-up
Knowledge Insufficient (≤ 50%
correct)
288 (75.2%) 87 (85.3%) 88 (88.0%) Χ2(2) = 10.71, P =
.005
Sufficient 95 (24.8%) 15 (14.7%) 12 (12.0%)
Attitudes Negative 280 (75.1%) 68 (69.4%) 59 (62.8%) X2(4) = 7.84, P =
.098
Neutral 83 (22.3%) 24 (24.5%) 30 (31.9%)
Positive 10 (2.7%) 6 (6.1%) 5 (5.3%)
Uptake at follow-
up
No decision 171 (44.8%) 67 (65.7%) 70 (70.0%) Χ2(4) = 29.06, P
<.001
Take tamoxifen 0 0 0
Take raloxifenea 2 (0.5%) 0 0
Decided no drug 209 (54.7%) 35 (34.3%) 30 (30.0%)
a Three-month control group did not complete measures at post-test.
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Follow-up knowledge, attitudes and behavior
In the follow-up survey, we assessed knowledge, attitudes
and uptake of tamoxifen and raloxifene over the previous
three months. While 62% of the intervention group met
criteria for sufficient knowledge at post-test, only 25% met
these criteria at follow-up, showing a steep decline in
retention of information (Table 2). Sufficient knowledge
was demonstrated by 15% of standard control participants
and 12% of three-month control participants. Differences
between the intervention and control groups were statisti-
cally significant, (Χ2 (2) = 10.71, P = .005).
Attitudes toward uptake of chemoprevention were
generally negative in all groups (75% intervention, 70%
standard control, 63% three-month control (see Table 2)
and did not differ across groups, X2(4) = 7.84, P = .098.
Intervention participants were more likely to report
having made a decision (versus being undecided) about
starting chemoprevention, Χ2(4) = 29.06, P <.001. Among
intervention participants, two women (1%) decided to take
raloxifene, 45% were undecided, and 55% decided against
chemoprevention drugs. No standard control participants
decided to take a drug (0%), 66% were undecided and 34%
decided against chemoprevention drugs. No three-month
control group participants decided to take a drug (0%),
70% were undecided and 30% decided against chemopre-
vention drugs (Table 2).
Participants in the intervention group most often
showed alignment between attitudes and decisions (68%
intervention, 55% standard control, 54% three-month
control), X2(2) = 9.85, P = 0.007 (data not shown).
Follow-up informed choice
At three months, 17% of the intervention group’s choices
about uptake of chemoprevention could be considered
‘informed’ according to our definition (Table 3). These
were all decisions to not take tamoxifen or raloxifene.
Two women decided to use raloxifene, but these choices
were uninformed because they either had insufficient
knowledge (n = 1) or a neutral attitude (n = 1). In the con-
trol groups, 12% (standard control) and 8% (three-month
control) of choices were informed (Table 3). Differences in
rates of informed choices between groups were statistically
insignificant, Χ2(2) = 5.40, P = 0.067.
Latent informed choices
Because knowledge was so low at follow-up and because
it is likely that people made decisions based on post-test
(latent) knowledge [23] we also examined informed
decision making at three months using the post-test
levels of sufficient knowledge. This way, 44% of the
intervention group’s choices about uptake of chemopre-
vention at three months could be considered ‘informed’,
whereas only 3% of the standard control groups’ choices
were informed, Χ2(1) = 58.54, P <0.001 (Table 3).
Discussion
In this study, Marteau’s model [17] was used to determine
whether the DA increased the number of informed
choices about uptake of tamoxifene and raloxifene. In fact,
our data revealed that women given a DA were more likely
to have made an informed choice about uptake of
Table 3 Informed decisions: post-test, latent, and three-month follow-up, frequencies (%)
Intervention
(n = 383)
Standard control (n =
102)





Negative attitudes, uptake unlikely 180 (47.0%) 4 (3.9%) -
Neutral attitudes, uptake neither likely nor
unlikely
15 (3.9%) 2 (2.0%) -
Positive attitudes, uptake likely 7 (1.8%) 0 -
Total post-test informed decisions 202 (52.7%) 6 (5.9%) X2 (1) = 71.97, P <0.001
Follow-up informed decisionsb
Negative attitudes, decided against drug 48 (12.5%) 6 (5.9%) 1 (1.0%)
Neutral attitudes, no decision made 17 (4.4%) 6 (5.9%) 7 (7.0%)
Positive attitudes, decided to take drugc 0 0 0
Total follow-up informed decisions 65 (16.9%) 12 (11.8%) 8 (8.0%) X2 (2) = 5.40, P = 0.067
Latent knowledge informed decisionsb d
Negative attitudes, decided against drug 131 (34.2%) 3 (2.9%) -
Neutral attitudes, no decision made 36 (9.4%) 0 -
Positive attitudes, decided to take drugc 0 0 -
Total latent informed decisions 167 (43.6%) 3 (2.9%) X2 (1) = 58.54, P <0.001
a Three-month control group did not complete measures at post-test; In all cases of informed decision making level of knowledge needs to be sufficient.
Attitudes should align with likelihood of taking the drug. Participants in the three-month control group did not answer knowledge questions at post-test; c At
three3 month follow-up, of the two participants who decided to take raloxifene, one had sufficient knowledge but neutral attitudes and one had insufficient
knowledge and positive attitudes. d Latent informed decisions consisted of sufficient post-test knowledge, and aligned attitudes and decisions at follow-up.
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tamoxifen and raloxifene than women who did not view
the DA. Also, fewer women in the intervention group
remained undecided about uptake of the drugs. As
expected, three months after baseline the rate of informed
decision making about actual uptake was still marginally
higher in women who had received the DA, particularly
because of declining knowledge levels. However, overall,
levels of informed decision making are strikingly low.
Since most respondents had negative attitudes toward
uptake of tamoxifen and raloxifene and most decided not
to take chemoprevention drugs, uninformed choices were
mainly related to insufficient knowledge. One potential
reason for relatively low rates of knowledge in the group
receiving the DA is that each drug had five risks and two
benefits presented. The amount of information conveyed
may have been overwhelming and reduced people’s recall,
even though we asked about gist-level information [23].
The rate of informed choices in the intervention
group decreased from 54% (post-test) to 18% (three-
month follow-up), but attitudes did not change from
post-test to follow-up. The observed decline in
informed choices is mainly due to decreased knowledge
scores over time and measuring latent decision-making
appears to be useful. This raises an interesting question
- how long are decision-makers supposed to remember
gist-level information once they have come to a
decision?
Another issue is the important influence of the defi-
nition of what exactly constitutes ‘sufficient decision-
relevant knowledge’ on the resulting proportion of
informed choice. Consensus is needed on the levels of
knowledge and specific content necessary to make
informed decisions. A drawback of the complicated
nature of the information being provided, and thus a
limitation of this study, is that there were not enough
participants with more than 50% knowledge retention
to examine differences between groups.
One might expect that women who consider taking
chemoprevention drugs are more likely to remember
information because it is relevant to their decision,
whereas women who have already decided not to take
the drugs may be less motivated to remember the infor-
mation. However, we did not find this effect.
Traditionally two kinds of informed choices are distin-
guished: sufficient decision-relevant knowledge combined
with either positive attitudes and acceptance of the pre-
ventive measure or negative attitudes and a decline of the
preventive measure [17]. We identified a third type of
informed choice, which is the combination of sufficient
knowledge, neutral attitudes and being undecided about
uptake of the preventive measure. The question is whether
this third combination indeed reflects an informed choice
rather than ambivalent attitudes, since – as shown by
earlier research – ambivalence may lead to postponing
decision making [26]. We recommend further study into
this topic.
It has often been shown that DAs lead to increased
levels of knowledge in those who have used them [27].
While many studies of DAs examine changes in knowl-
edge, attitudes, intentions and behavior, few examine the
relationship between knowledge and the concordance
between attitudes, intentions, and behavior. Even for well-
known population-based screening programs, such as
breast or cervical cancer screening, interventions
specifically aimed at improving informed decision-making
are limited [28,29]. This study, therefore, represents a
valuable contribution to the literature. Our study has sev-
eral limitations related to generalizability of the findings.
First, despite oversampling eligible African American
women, participants were mostly White. Other chemopre-
vention studies have also encountered this problem
[1,5,6,10,21]. Second, we used an online DA, which can
ultimately increase intervention reach, but lack of Internet
access or discomfort with using the Internet likely
narrowed the pool of potential participants and possibly
directed access to a more educated sample. However, find-
ings of previous research comparing Internet samples to
other samples are inconsistent in this regard [30,31].
Third, we assessed attitudes with one item. Although this
single item enabled the registration of negative attitudes
considering own participation in the intervention - which
is often not the case when attitudes are being assessed -
we acknowledge that using one item is a bit limited.
While the above limitations decrease external validity of
our study, including two control groups significantly
strengthens internal validity. The standard control group
allows us to test the effects of the DA compared to not
receiving any information about tamoxifen and raloxifene,
while the three-month control group allows us a clean
control group to evaluate the impact of the DA over time.
Our results may generalize to other insured patients, as we
recruited participants from two geographically diverse
health plan populations.
Practice implications
Women given a DA describing risks and benefits of tamox-
ifen and raloxifene were significantly more likely to make
informed decisions about undergoing chemoprevention for
breast cancer. The intervention materials impacted not
only knowledge but also alignment of attitudes with deci-
sions. The online DA format makes this a potentially valu-
able adjunct in clinical practice, since women could utilize
it prior to clinic visits. Finally, this study suggests a valuable
way to evaluate the effectiveness of DAs.
Conclusions
While informed decisions cannot, by definition, be made
without sufficient relevant knowledge [17], it is also
Korfage et al. Breast Cancer Research 2013, 15:R74
http://breast-cancer-research.com/content/15/5/R74
Page 7 of 9
important that attitudes align with intentions and actual
behavior. In this study, women in the intervention
group more often had made decisions about uptake of
tamoxifen and raloxifene that aligned with their
attitudes.
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